New opportunities for overweight* and obesity pharmacotherapy

Paweł Bogdański

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

2/2017
vol. 3

Send email

Copy url:

abstract:

Review paper

**New opportunities for overweight* and obesity pharmacotherapy**

Paweł Bogdański

Online publish date: 2017/05/18

View full text Get citation

Results of epidemiological studies show a permanent increase in overweight and obesity prevalence. It was demonstrated beyond reasonable doubt that overweight leads to many adverse health consequences. Realistic goals and timeframe estimation are crucial for obesity treatment. Patients should also be motivated in a proper way. A comprehensive program for weight reduction should be based on diet modification, increase in physical activity and behavioral therapy. In some patients pharmacotherapy can be considered. A new medicinal product available on the market since November 2016 under the trade name Mysimba provides wider possibilities of pharmacological treatment and increases chances for efficacious management of overweight* and obesity.

keywords:

New opportunities for overweight* and obesity pharmacotherapy

Paweł Bogdański

obesity, overweight, pharmacotherapy, Mysimba, naltrexone, bupropion

**New opportunities for overweight* and obesity pharmacotherapy**